Xu Feng, Kotarba AnnMarie E, Ou-Yang Ming-Hsuan, Fu Ziao, Davis Judianne, Smith Steven O, Van Nostrand William E
From the Departments of Neurosurgery and Medicine and.
Biochemistry and Cell Biology, Stony Brook University, Stony Brook, New York 11794-8122.
J Biol Chem. 2014 Jun 20;289(25):17895-908. doi: 10.1074/jbc.M113.536565. Epub 2014 May 14.
The fibrillar assembly and deposition of amyloid β (Aβ) protein, a key pathology of Alzheimer disease, can occur in the form of parenchymal amyloid plaques and cerebral amyloid angiopathy (CAA). Familial forms of CAA exist in the absence of appreciable parenchymal amyloid pathology. The molecular interplay between parenchymal amyloid plaques and CAA is unclear. Here we investigated how early-onset parenchymal amyloid plaques impact the development of microvascular amyloid in transgenic mice. Tg-5xFAD mice, which produce non-mutated human Aβ and develop early-onset parenchymal amyloid plaques, were bred to Tg-SwDI mice, which produce familial CAA mutant human Aβ and develop cerebral microvascular amyloid. The bigenic mice presented with an elevated accumulation of Aβ and fibrillar amyloid in the brain compared with either single transgenic line. Tg-SwDI/Tg-5xFAD mice were devoid of microvascular amyloid, the prominent pathology of Tg-SwDI mice, but exhibited larger parenchymal amyloid plaques compared with Tg-5xFAD mice. The larger parenchymal amyloid deposits were associated with a higher loss of cortical neurons and elevated activated microglia in the bigenic Tg-SwDI/Tg-5xFAD mice. The periphery of parenchymal amyloid plaques was largely composed of CAA mutant Aβ. Non-mutated Aβ fibril seeds promoted CAA mutant Aβ fibril formation in vitro. Further, intrahippocampal administration of biotin-labeled CAA mutant Aβ peptide accumulated on and adjacent to pre-existing parenchymal amyloid plaques in Tg-5xFAD mice. These findings indicate that early-onset parenchymal amyloid plaques can serve as a scaffold to capture CAA mutant Aβ peptides and prevent their accumulation in cerebral microvessels.
淀粉样β(Aβ)蛋白的纤维状组装和沉积是阿尔茨海默病的关键病理特征,可表现为实质淀粉样斑块和脑淀粉样血管病(CAA)。家族性CAA在不存在明显实质淀粉样病理的情况下存在。实质淀粉样斑块和CAA之间的分子相互作用尚不清楚。在这里,我们研究了早发性实质淀粉样斑块如何影响转基因小鼠微血管淀粉样蛋白的发展。将产生非突变人类Aβ并发展为早发性实质淀粉样斑块的Tg-5xFAD小鼠与产生家族性CAA突变人类Aβ并发展为脑微血管淀粉样蛋白的Tg-SwDI小鼠进行杂交。与单一转基因品系相比,双转基因小鼠大脑中Aβ和纤维状淀粉样蛋白的积累有所增加。Tg-SwDI/Tg-5xFAD小鼠没有微血管淀粉样蛋白(Tg-SwDI小鼠的主要病理特征),但与Tg-5xFAD小鼠相比,表现出更大的实质淀粉样斑块。在双转基因Tg-SwDI/Tg-5xFAD小鼠中,更大的实质淀粉样沉积物与更高的皮质神经元损失和活化小胶质细胞增加有关。实质淀粉样斑块的周边主要由CAA突变Aβ组成。非突变Aβ纤维种子在体外促进CAA突变Aβ纤维的形成。此外,在Tg-5xFAD小鼠中,海马内注射生物素标记的CAA突变Aβ肽会在预先存在的实质淀粉样斑块上及其附近积累。这些发现表明,早发性实质淀粉样斑块可以作为一个支架来捕获CAA突变Aβ肽,并防止它们在脑微血管中积累。